CN114502150B - Pharmaceutical composition for treating viral influenza and preparation thereof - Google Patents
Pharmaceutical composition for treating viral influenza and preparation thereof Download PDFInfo
- Publication number
- CN114502150B CN114502150B CN202080062567.5A CN202080062567A CN114502150B CN 114502150 B CN114502150 B CN 114502150B CN 202080062567 A CN202080062567 A CN 202080062567A CN 114502150 B CN114502150 B CN 114502150B
- Authority
- CN
- China
- Prior art keywords
- compound
- salt
- pharmaceutical composition
- oseltamivir
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 206010022000 influenza Diseases 0.000 title abstract description 13
- 230000003612 virological effect Effects 0.000 title description 6
- 229940125904 compound 1 Drugs 0.000 claims description 115
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 75
- 229960002194 oseltamivir phosphate Drugs 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 29
- 229960003752 oseltamivir Drugs 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 10
- 159000000000 sodium salts Chemical class 0.000 claims description 10
- 159000000007 calcium salts Chemical class 0.000 claims description 9
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- -1 glidants Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 3
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 3
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Chemical class 0.000 claims description 3
- 239000001923 methylcellulose Chemical class 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 241000220479 Acacia Species 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 27
- 241000700605 Viruses Species 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 238000011156 evaluation Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 description 19
- 241000712461 unidentified influenza virus Species 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000002195 synergetic effect Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 10
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 9
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 8
- 229960001084 peramivir Drugs 0.000 description 8
- 229960001028 zanamivir Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002911 sialidase inhibitor Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JGPXDNKSIXAZEQ-SBBZOCNPSA-N (2s,3s)-3-[[5-fluoro-2-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C1=C(F)C=C2C(C=3N=C(C(=CN=3)F)N[C@H]3C4CCC(CC4)[C@@H]3C(=O)O)=CNC2=N1 JGPXDNKSIXAZEQ-SBBZOCNPSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940124393 anti-influenza virus drug Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229950004058 pimodivir Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 229940061367 tamiflu Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000312 effect on influenza Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pharmaceutical composition and a preparation thereof, the pharmaceutical composition comprises two effective components with a mass ratio in a specific range, the pharmaceutical composition has an obviously better anti-influenza virus effect, and the pharmaceutical composition is considered to have a better patent medicine prospect after comprehensive evaluation.
Description
Technical Field
The invention belongs to the field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition for treating viral influenza and a preparation containing the pharmaceutical composition.
Background
Influenza virus, i.e., influenza virus (IFV), is a segmented, single-stranded, antisense RNA virus that can cause influenza in humans and animals. According to the World Health Organization (WHO) statistics, seasonal epidemics of influenza every year can cause 300 to 500 million severe cases worldwide, 29 to 65 million cases die, and each influenza pandemic causes great damage to global public health and economy.
The current clinical scheme of influenza includes vaccination and chemotherapy and chemoprevention with antiviral drugs, wherein one of the important antiviral drugs is neuraminidase inhibitor, such as Oseltamivir (OSE), zanamivir (zanamivir), peramivir (Peramivir), and the like, and the antiviral drugs have obvious effect on influenza a virus and are common drugs for treating viral influenza in clinic. However, similar to antibiotic products, the resulting drug resistance is becoming more severe with the long-term use of antiviral products. According to the monitoring data of the WHO western Pacific region, the following data are shown: the proportion of oseltamivir drug-resistant strains of seasonal influenza A H1N1 virus in China 2008-2009 reaches 28%, and the drug resistance of influenza virus affects the treatment effect of the existing anti-influenza virus drugs.
Wherein, the oseltamivir is metabolized and converted into the active metabolite oseltamivir carboxylic acid after being orally taken to exert drug effect, and the process of releasing the virus from infected host cells is interfered by competitively combining with the active site of influenza virus neuraminidase, thereby reducing the spread of influenza A or B virus.
Patent WO2018041263 discloses a series of pyrimidine derivatives. In vitro activity data show that part of compounds show positive effects in an influenza virus replication inhibition test, and in a further animal test, part of compounds also show remarkable treatment effects on influenza A virus H1N1 mouse infection models, wherein the comprehensive performance of the compound 1 (example 4, WX-216) is relatively outstanding, and the compound 1 is considered to have better patent medicine prospects.
On the other hand, influenza viruses have the characteristics of high mutation rate, multiple virus recombination phenomena and the like, and although new-structure and new-mechanism active compounds are continuously discovered, in the long run, the defects that the virus concentration in the body cannot be effectively inhibited/reduced and the viral cold is cured by using a single antiviral medicament possibly exist, and the corresponding increase of the using dosage and the prolonging of the treatment time bring great medication risks to patients. Finberg RW et al, J Infect Dis,2019Mar 15;219 (7) 1026-1034, a combined medication experiment of Pimodivir and oseltamivir is disclosed, and the result shows that the combined use of 600mg of Pimodivir and 75mg of oseltamivir can reduce the load of the influenza A virus to the maximum extent.
Therefore, the search for a new solution to solve the drug resistance problem of new products with clinical prospects and reduce the occurrence probability of adverse drug reactions so as to meet the great demand of anti-influenza virus drugs which are not met clinically at present is a technical problem to be solved urgently in the prior art.
Disclosure of Invention
The first purpose of the present invention is to overcome at least one of the deficiencies of the prior art, and to provide a pharmaceutical composition for treating viral influenza, which utilizes the synergistic effect between the effective components to solve the technical problems of drug resistance of influenza virus, etc., and can effectively reduce the clinical medication risk, and after comprehensive evaluation, the pharmaceutical composition has a good prospect of patent medicine.
The purpose of the invention is realized by the following technical scheme:
a pharmaceutical composition comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is compound 1, its corresponding ester, its corresponding salt, its corresponding ester salt, or a combination thereof; the second effective component is neuraminidase inhibitor; the mass ratio of the first effective component to the second effective component is 1-8:1.
The first effective component refers to a mixture obtained by mixing one or more than two of compound 1, ester corresponding to compound 1, salt of compound 1 and salt of ester corresponding to compound 1 in any proportion.
The compound 1, the ester corresponding to the compound 1, the salt of the compound 1, and the salt of the ester corresponding to the compound 1 each include an anhydrate, a hydrate, and a solvate thereunder.
The ester corresponding to compound 1 refers to the ester formed by compound 1 and organic acid, including but not limited to methyl ester, ethyl ester, propyl ester, isopropyl ester, n-butyl ester, tert-butyl ester and the like of compound 1.
The salt of the compound 1 is a salt of the compound 1 with an organic acid and/or an inorganic acid, or a salt of the compound 1 with an organic base and/or an inorganic base, and includes, but is not limited to, a hydrochloride, a hydrobromide, a sulfate, a phosphate, a benzenesulfonate, a p-toluenesulfonate, a methanesulfonate, a tartrate, a camphorsulfonate, a lithium salt, a sodium salt, a potassium salt, a calcium salt, a magnesium salt, an aluminum salt, an ammonium salt, an ethylenediamine salt, a triethylamine salt, and the like of the compound 1.
The salt of the ester corresponding to compound 1 refers to the salt of the ester formed by compound 1 and an organic acid and/or an inorganic base and/or an organic acid and/or an inorganic acid, and includes, but is not limited to, hydrochloride of methyl ester of compound 1, sulfate of methyl ester of compound 1, hydrochloride of ethyl ester of compound 1, sulfate of ethyl ester of compound 1, and the like.
The neuraminidase inhibitor indicated by the second active ingredient is a mixture obtained by mixing one or more of Oseltamivir (Oseltamivir) or a derivative thereof, zanamivir (zanamivir) or a derivative thereof, peramivir (Peramivir) or a derivative thereof and the like in any proportion; the derivatives of Oseltamivir (Oseltamivir), zanamivir (zanamivir) and Peramivir (Peramivir) are independently selected from acids and/or bases thereof, and may also be esters, amides formed by further hydrolysis of the compounds, or other derivatives of carboxylic acids and salts thereof obtained by hydrolysis, and each of the derivatives includes the following anhydrous compounds, solvates, hydrates and solvates, for example, oseltamivir or its derivative may be selected from Oseltamivir free form, and may also be selected from Oseltamivir phosphate, oseltamivir carboxylic acid, osemivir carboxylate, and the like.
The mass ratio of the first effective component to the second effective component is 1-8:1, preferably, the mass ratio of the first effective component to the second effective component is 100-600; specifically, the mass ratio of the first active ingredient to the second active ingredient is about 100.
Unless otherwise specified, the mass of the salt in the present invention refers to the mass of the compound before metabolism (free base/acid equivalent), the mass of the hydrate/solvate refers to the mass of the compound on a dry basis (on an anhydrous basis), and the mass of the metabolite (e.g., carboxylic acid obtained by ester hydrolysis) refers to the mass of the compound before metabolism.
According to a preferable technical scheme of the invention, the first effective component in the pharmaceutical composition is a compound 1, and the second effective component is oseltamivir phosphate; the mass ratio of the compound 1 to the oseltamivir phosphate in the pharmaceutical composition is 100-600; specifically, the mass ratio of the compound 1 to oseltamivir phosphate is about 100, 75, 200.
According to a preferable technical scheme of the invention, the first effective component in the pharmaceutical composition is a sodium salt of the compound 1, and the second effective component is oseltamivir phosphate; the mass ratio of the sodium salt of the compound 1 to the oseltamivir phosphate in the pharmaceutical composition is 100-600; specifically, the mass ratio of the sodium salt of compound 1 to oseltamivir phosphate is about 100, 75, 200.
According to a preferable technical scheme of the invention, the first effective component in the pharmaceutical composition is hydrochloride of the compound 1, and the second effective component is oseltamivir phosphate; the mass ratio of the hydrochloride of the compound 1 to the oseltamivir phosphate in the pharmaceutical composition is 100-600; specifically, the mass ratio of the hydrochloride of the compound 1 to the oseltamivir phosphate is about 100, 75, 200.
According to a preferable technical scheme of the invention, the first effective component in the pharmaceutical composition is a potassium salt of the compound 1, and the second effective component is oseltamivir phosphate; the mass ratio of the potassium salt of the compound 1 to the oseltamivir phosphate in the pharmaceutical composition is 100-600; specifically, the mass ratio of the potassium salt of compound 1 to the oseltamivir phosphate is about 100, 75, 200.
According to a preferable technical scheme of the invention, the first effective component in the pharmaceutical composition is a calcium salt of the compound 1, and the second effective component is oseltamivir phosphate; the mass ratio of the calcium salt of the compound 1 to the oseltamivir phosphate in the pharmaceutical composition is 100-600; specifically, the mass ratio of the calcium salt of compound 1 to oseltamivir phosphate is about 100, 75, 200.
According to a preferable technical scheme of the invention, the first effective component in the pharmaceutical composition is p-toluenesulfonate of the compound 1, and the second effective component is oseltamivir phosphate; the mass ratio of the p-toluenesulfonate of the compound 1 to the oseltamivir phosphate in the pharmaceutical composition is 100-600; specifically, the mass ratio of the tosylate salt to oseltamivir phosphate of compound 1 is about 100, 75, 200.
The inventors have surprisingly found in experiments that: when the mass ratio of the first active ingredient (compound 1, the corresponding ester thereof, the corresponding salt thereof, the corresponding ester salt thereof, or the combination thereof) to the second active ingredient (the neuraminidase inhibitor) is within a specific range, the pharmaceutical composition has a good pharmaceutical synergistic effect, and shows an effect against influenza virus that is significantly better than that of a single ingredient, and also shows an effect against influenza virus that is significantly better than that of a pharmaceutical composition having a mass ratio outside the specific range, and it is known that when the mass ratio of the first active ingredient to the second active ingredient in a unit preparation is within the specific range, the pharmaceutical composition has a better effect against influenza virus; the medicine composition is considered to have better medicine-forming prospect after the evaluation of the properties (such as mixture stability, fluidity and the like) of other medicine-forming materials.
Another objective of the present invention is to disclose a method for preparing the aforementioned pharmaceutical composition, which can ensure the stable preparation of the aforementioned pharmaceutical composition. Specifically, the preparation method adopts a mixing method which is conventional in the field; more specifically, the preparation method can be a direct mixing method, an equivalent incremental method and the like, the used mixing equipment can be mixing equipment which is common in the field according to the preparation scale, such as a V-shaped mixer, a double cone mixer, a rotary mixer and the like, and the preparation can also be realized in a manual mixing mode during small-scale preparation.
The third purpose of the invention is to disclose a preparation containing the pharmaceutical composition. Specifically, the preparation comprises the pharmaceutical composition and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is selected from one or more than two of filler, adhesive, disintegrant, glidant, lubricant, flavoring agent and the like.
Specifically, the filler is selected from one or a mixture of two or more of calcium carbonate, magnesium carbonate, calcium phosphate, calcium sulfate, magnesium oxide, calcium carboxymethylcellulose, sodium carboxymethylcellulose, sucrose, lactose, fructose, xylitol, mannitol, starch or a derivative thereof, dextrin, microcrystalline cellulose, and the like, which are mixed at an arbitrary ratio.
Specifically, the binder is selected from one or a mixture of two or more of acacia, gelatin, tragacanth, dextrin, polyvinylpyrrolidone, starch and derivatives thereof, sodium alginate, sorbitol, syrup, hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, ethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, glucose, polymethacrylate, and the like, which are mixed in an arbitrary ratio.
Specifically, the disintegrating agent is selected from one or a mixture of two or more of starch, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, croscarmellose sodium, crospovidone, low-substituted hydroxypropylmethylcellulose, microcrystalline cellulose, and methylcellulose, which are mixed at an arbitrary ratio.
Specifically, the glidant is selected from one or a mixture of more than two of colloidal silicon dioxide, powdered cellulose, magnesium trisilicate, silicon dioxide, talcum powder and the like which are mixed in any proportion.
Specifically, the lubricant is selected from one or more of calcium stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, microcrystalline cellulose, sodium benzoate, sodium chloride, sodium lauryl sulfate, sodium stearyl fumarate, talcum powder, zinc stearate, polyethylene glycol and the like, and is a mixture obtained by mixing the two or more of the calcium stearate, the glyceryl monostearate, the glyceryl palmitostearate, the magnesium stearate, the microcrystalline cellulose, the sodium benzoate, the sodium chloride, the sodium lauryl sulfate, the sodium stearyl fumarate, the talcum powder, the zinc stearate, the polyethylene glycol and the like in any proportion.
Specifically, the flavoring agent is selected from one or more than two of stevioside, aspartame, other essences and sweeteners commonly used in the field, and the like, which are mixed in any proportion.
The preparation containing the pharmaceutical composition is an oral preparation, and specifically can be powder, granules, pellets, capsules, tablets, solutions or lozenges.
Based on the beneficial effects of the aforementioned pharmaceutical compositions, such as: the preparation containing the pharmaceutical composition also has obviously better anti-influenza virus effect compared with the preparation containing single component, and also has obviously better anti-influenza virus effect compared with the preparation containing the pharmaceutical composition with mass ratio outside the specific range, thereby having better market prospect.
Compared with the prior art, the invention has the following outstanding advantages and beneficial effects:
1. the pharmaceutical composition comprises a first active ingredient (compound 1, a corresponding ester thereof, a corresponding salt thereof, a corresponding ester salt thereof or a combination thereof) and a second active ingredient (a neuraminidase inhibitor) in a specific mass ratio, and has a better pharmaceutical synergistic effect, wherein the neuraminidase inhibitor has the best effect on oseltamivir and/or oseltamivir salt and/or oseltamivir carboxylic acid or oseltamivir carboxylate obtained after hydrolysis of oseltamivir, and the pharmaceutical composition is considered to have better pharmaceutical prospects after comprehensive evaluation.
2. Provides a preparation method of the pharmaceutical composition, which can ensure the stable preparation of the pharmaceutical composition.
3. The preparation containing the pharmaceutical composition has a better anti-influenza virus effect than a preparation containing a single component, and has a better market prospect.
The present invention is attributed to the discovery that a combination of drugs in a specific range has a synergistic effect, and therefore, it will be understood by those skilled in the art that a combination of drugs in a unit dosage unit within the range of the present invention can be considered to be the subject of the present invention; in particular, the aforementioned unit dosage unit refers to the smallest unit for clinical use, such as: tablets per unit tablet, capsules per unit granule, oral liquid per unit bottle, granules per unit pack, and the like.
Detailed Description
The present invention will be described in further detail with reference to examples, but the embodiments of the invention are not limited thereto.
The oseltamivir phosphate used in the examples is the bulk drug of the marketed preparation tamiflu, CAS:204255-11-8 with purity >99%; the oseltamivir is a free product of a bulk drug of a commercially available preparation tamiflu, and the CAS:196618-13-0 with purity >99%; oseltamivir carboxylic acid used was a commercially available intermediate, CAS:187227-45-8 with purity >99%.
The zanamivir (CAS: 139110-80-8) and the peramivir (CAS: 229614-55-5) used in the examples are bulk drugs of commercial preparations, and the purity is more than 99%.
EXAMPLE 1 preparation of Compound 1
The compound 1 is prepared by the method disclosed in WO2018041263, example 4, and the structural characterization proves that the obtained product is the compound 1.
EXAMPLE 2 preparation of hydrochloride salt of Compound 1
5g of Compound 1 was charged into a 250mL eggplant-shaped bottle, THF (100 mL) was added, 0.98mL of hydrochloric acid (concentrated hydrochloric acid dissolved in 9mL of THF) was added, and the mixture was stirred at 30 ℃ for 12 hours, and the solid was filtered, and the filter cake was dried under vacuum at 40 ℃ to obtain the hydrochloride of Compound 1.
EXAMPLE 3 preparation of p-Toluenesulfonic acid salt of Compound 1
5g of Compound 1 was put in a 250mL eggplant-shaped bottle, THF (100 mL) was added, p-toluenesulfonic acid monohydrate (2.26 g dissolved in 10mL of THF) was added, and the mixture was stirred at 30 ℃ for 12 hours, and the solid was filtered, and the filter cake was dried under vacuum at 40 ℃ to obtain a solid (0.425 g). This solid (0.101 g) was added to acetone (2 mL) and slurried for 12h to give the p-toluenesulfonate salt of Compound 1.
EXAMPLE 4 preparation of sodium salt of Compound 1
5g of Compound 1 was placed in a 250mL eggplant-shaped flask, THF (100 mL) was added, an aqueous NaOH solution (0.477 g, dissolved in 1mL of water) was added, stirring was carried out at 30 ℃ for 12 hours, the solid was filtered, and the filter cake was dried under vacuum at 40 ℃ to obtain the sodium salt of Compound 1.
EXAMPLE 5 preparation of Potassium salt of Compound 1
2g of Compound 1 was weighed into a 100mL eggplant-shaped bottle, THF (35 mL) was added, an aqueous KOH solution (0.255 g, dissolved in 0.5mL of water and 5mL of THF) was added, and the mixture was stirred at 30 ℃ for 12 hours, followed by solid filtration and vacuum drying of the cake at 40 ℃ to obtain a potassium salt of Compound 1.
EXAMPLE 6 preparation of calcium salt of Compound 1
2g of compound 1 was put in a 100mL eggplant-shaped bottle, THF (35 mL) was added, an aqueous calcium hydroxide solution (0.168 g, dissolved in 0.5mL of water and 5mL of THF) was added, stirring was performed at 25 ℃ for 12 hours, the solid was filtered, the cake was dried under vacuum at 40 ℃ to obtain a solid (1.440 g), the solid (0.204 g) was dissolved in a mixed solvent of ethanol and water (ethanol: water = 3:1) (4 mL) and slurried, stirring was performed at 25 ℃ for 12 hours, the solid was filtered, and the cake was dried under vacuum at 40 ℃ to obtain a calcium salt of compound 1.
Example 7
200g of the compound 1 prepared in example 1 is taken and mixed with 75g of oseltamivir phosphate (calculated as oseltamivir) uniformly to obtain a pharmaceutical composition with the mass ratio of 200.
Example 8
In the same manner as in example 7, a pharmaceutical composition containing compound 1 and oseltamivir phosphate in the mass ratio of 50, 75, 100, 300, 400.
Using the same procedure as in example 7, a pharmaceutical composition was prepared using the salt of compound 1 prepared in examples 2-6, and oseltamivir or oseltamivir phosphate, both in a mass ratio of 50, 75, 100, 75,200, 300, 75,400, 75,500, 75,600, 700.
Example 9 comparative in vitro Activity assay
1. Purpose of experiment
The compound 1 and oseltamivir carboxylic acid (active metabolite) are taken as research objects, the synergistic inhibition effect of the compound 1 and oseltamivir (or oseltamivir carboxylic acid) on influenza A virus is analyzed under a certain proportion, the plasma protein binding rate of the compound 1 and oseltamivir carboxylic acid is combined, and the in vivo combined effect is converted and predicted.
2. Experimental Material
Virus: A/Aichi/2/1968 (H3N 2), available from ATCC.
Cell: dog Kidney epithelial cell line (Madin-Darby Canine Kidney Cells, MDCK).
The drug dissolution method comprises the following steps: dissolving the compound 1 and an oseltamivir active metabolite (oseltamivir carboxylic acid, calculated as oseltamivir) by using dimethyl sulfoxide (DMSO), and preparing a 100mM/L mother solution for storage; then diluted with the culture Medium Minimum Essential Medium (MEM) as a working solution (note: DMSO final concentration is 1%).
3. Experimental methods
MDCK cells were approximately 2.5X 10 per well 4 The cells were seeded in a 96-well plate, and after the cells grew into a monolayer (about 24 hours), the culture medium was discarded, and the cell surface was washed 2 times with PBS. Adding 100 μ L/well of virus dilution containing MOI =0.01, 37 deg.C, 5% CO 2 After incubation for 2h in the incubator, the virus solution was discarded, and 2-fold dilution containing compound 1 and oseltamivir carboxylic acid was added to the medium to obtain different concentrations and 0nM combination (i.e., 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625, 0nM for compound 1; 0.25, 0.125, 0.0625, 0.03125, 0. Mu.M for oseltamivir carboxylic acid). Adding 100 μ L/well of the combined medicine into 96-well cells, setting 3 multiple wells for each concentration, and setting a normal cell group, a virus control group and a medicine control group; placing at 37 ℃ and 5% of CO 2 After incubation in an incubator, the cytopathic condition was observed daily, and then the cell viability of each well was measured using MTT, and the results of virus inhibition after 72 hours of observation are shown in table 1 below.
TABLE 1 combination of Compound 1 with oseltamivir carboxylic acid anti-A/Aichi/2/1968 (H3N 2) (% inhibition)
From the above data, when compound 1: the molar ratio of oseltamivir carboxylic acid is between 0.03125 μ M and 0.015625 nm
When the ratio of nM to 0.25 muM (1.5-16000), the synergistic inhibition effect on tested influenza virus is obvious, and the specific expression is that the virus inhibition rate after combination is higher than that of single-drug virus; in view of the fact that after the compound 1 enters a human body, the binding rate of plasma protein can reach 99.9%, the compound 1 in a free state in the body accounts for about 0.1%, and the binding rate of oseltamivir carboxylic acid in the plasma protein of the human body is 0.3%, and the oseltamivir carboxylic acid in the free state in the body accounts for about 99.7%; upon conversion, i.e. in vivo, the molar ratio of compound 1 to oseltamivir carboxylic acid should be in the range of about 1:16 to 16:1, namely the mass ratio of the compound 1 to the oseltamivir is about 1:11.3 to 22.5:1 (440.
In subsequent experiments, the compound 1 has synergistic effect with oseltamivir, zanamivir and peramivir, but compared with other groups, the oseltamivir group has obviously better synergistic effect than other groups.
Example 10 in vivo Activity assay
Research on drug effect of drug on PR8 influenza virus
1. Study of drug on death protection of PR8 influenza virus (PR 8 virus 2h in advance)
Influenza virus with higher titer was cultured and BALB/C mice were infected with 2LD50 (lethal dose) nasal drops.
Groups administered for 5 consecutive days: gavage administration is carried out 2 times a day for 5 days 2h after infection, and a medicine composition compound 1 is set: 30mg/kg, compound 1:20mg/kg, compound 1:5mg/kg, compound 1:1.5mg/kg, oseltamivir phosphate: 10mg/kg, oseltamivir phosphate + compound 1=10mg/kg +30mg/kg, oseltamivir phosphate + compound 1=10mg/kg +20mg/kg, oseltamivir phosphate + compound 1=10mg/kg +5mg/kg, oseltamivir phosphate + compound 1=10mg/kg +1.5mg/kg; setting blank control groups and virus control groups, wherein each group contains 10 viruses; the observation is started from the first day of virus infection, the observation is continuously carried out for 14d, the weight change, the death condition and the like of the infected mice are observed and recorded every day, and the weight change, the death condition and the like of the infected mice are calculated according to the following formula:
mortality (%) = number of dead mice per group per total number before infection (one) × 100%
The results show that after the virus infection, the mice have symptoms of shortness of breath, rolling trembling, weight loss and the like, and have death; after continuous observation for 14d, the blank mice are in good state and have no death, and the death rate of the virus mice reaches 100 percent; compound 1: the 30mg/kg group has complete protection effect on infected mice, and the death rate of the group is 0 percent; compound 1: the 20mg/kg group has obvious protective effect on infected mice, and the death rate is 20%; compound 1: the mortality rate of mice in the 5mg/kg administration group was 80%; oseltamivir phosphate: 10mg/kg administration group and compound 1: the mortality rate of mice in the 1.5mg/kg administration group was 100%. After the compound 1 is combined with oseltamivir phosphate under the dosage of 5mg/kg and 20mg/kg, the death rate is obviously reduced, the synergistic effect is obvious, and the results are shown in a table 2:
TABLE 2 mortality and survival rates of the groups of mice
It can be seen that 5mg/kg, 20mg/kg compound 1 and 10mg/kg oseltamivir phosphate in combination exhibit good synergistic antiviral effects in a mouse model of drug action. Based on the conversion of the pharmacokinetic test results of the compound 1 and the oseltamivir phosphate in different species (a mouse and a healthy person), when the compound 1 is administered to the mouse at a dose of 5mg/kg and 20mg/kg, the in vivo exposure dose of the compound 1 is similar to that of 75mg and 600mg administered to a human body, and when the compound 1 is administered to the mouse at a dose of 10mg/kg, the in vivo exposure dose of the oseltamivir phosphate is similar to that of 75mg, the in-vivo exposure dose of the active metabolite administered to the human body, the combined drug effect of 600mg and 75mg of the compound 1 and 75mg of the oseltamivir phosphate is obvious, and the composition has a better in-vivo synergistic effect when the mass ratio of the compound 1 to the oseltamivir phosphate is 75-600 (1-8:1).
In combination with the above, the synergistic effect of the composition of the present invention is not consistent in vivo and in vitro; specifically, the composition shows inconsistency between in vivo and in vitro in a range of showing drug synergy and a more optimal range, and specifically shows that the composition is converted into a range of about 1.5 to 11.3 mass ratio of oseltamivir to compound 1 in vivo according to the range of showing drug synergy in vitro, and an in vivo experiment shows that the range of drug synergy is greatly reduced, and the composition shows that the composition shows synergy when the mass ratio of compound 1 to oseltamivir phosphate is 75-600 (1-8:1); further, when the mass ratio of the compound 1 to the oseltamivir phosphate is 75, 100, 200;
further expanded experiments show that when the compound 1, the corresponding ester thereof, the corresponding salt thereof, the corresponding ester salt thereof or the combination thereof and oseltamivir or oseltamivir phosphate also show basically consistent performance, the pharmaceutical composition of the compound 1 and the oseltamivir phosphate and the pharmaceutical composition of the sodium salt of the compound 1 and the oseltamivir phosphate have the best effect, and have better in vivo drug synergism on a wider range of viruses within the protection scope of the patent claims, so the compound 1, the corresponding ester, the corresponding salt thereof, the corresponding ester salt thereof or the combination thereof is considered to have better clinical prospect.
Example 11
The pharmaceutical composition obtained in example 7 is mixed with appropriate amount of filler, binder and disintegrant and then directly pressed into tablets (200mg + 75mg).
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such modifications are intended to be included in the scope of the present invention.
Claims (12)
1. A pharmaceutical composition, comprising a first active ingredient and a second active ingredient, wherein the first active ingredient is compound 1, a salt corresponding thereto, or a combination thereof; the second active ingredient is oseltamivir free state and/or oseltamivir phosphate and/or oseltamivir carboxylic acid and/or oseltamivir carboxylate; the mass ratio of the first effective component to the second effective component is 1-8:1;
2. the pharmaceutical composition according to claim 1, wherein the first active ingredient is a mixture of compound 1 and one or more salts of compound 1 mixed at any ratio.
3. The pharmaceutical composition according to claim 2, wherein the salt of compound 1 is a hydrochloride, sulfate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, tartrate, sodium salt, potassium salt, calcium salt thereof.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the mass ratio of the first active ingredient to the second active ingredient is 100 to 600.
5. The pharmaceutical composition according to any one of claims 1 to 3, wherein the mass ratio of the first effective ingredient to the second effective ingredient is from 100.
6. The pharmaceutical composition according to claim 1, wherein the first active ingredient is compound 1 and/or the sodium salt of compound 1 and/or the potassium salt of compound 1 and/or the hydrochloride salt of compound 1 and/or the calcium salt of compound 1 and/or the p-toluenesulfonate salt of compound 1; the second effective component is oseltamivir phosphate; the mass ratio of the compound 1 to the oseltamivir phosphate is 100-600.
7. The pharmaceutical composition according to claim 6, wherein the first active ingredient is compound 1 and/or the sodium salt of compound 1 and/or the potassium salt of compound 1 and/or the hydrochloride salt of compound 1 and/or the calcium salt of compound 1 and/or the p-toluenesulfonate salt of compound 1, and the second active ingredient is oseltamivir phosphate; the mass ratio of the compound 1 to the oseltamivir phosphate is 100.
8. A formulation comprising the pharmaceutical composition of any one of claims 1-7 and a pharmaceutically acceptable carrier.
9. The preparation according to claim 8, wherein the pharmaceutically acceptable carrier is selected from one or more of fillers, binders, disintegrants, glidants, lubricants and flavoring agents.
10. The preparation according to claim 9, wherein the filler is selected from the group consisting of calcium carbonate, magnesium carbonate, calcium phosphate, calcium sulfate, magnesium oxide, carboxymethylcellulose calcium, carboxymethylcellulose sodium, sucrose, lactose, fructose, xylitol, mannitol, starch or its derivatives, dextrin, and microcrystalline cellulose, and is a mixture obtained by mixing two or more thereof at any ratio; the binder is selected from one or more than two of acacia, gelatin, tragacanth, dextrin, polyvinylpyrrolidone, starch and derivatives thereof, sodium alginate, sorbitol, syrup, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, ethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, glucose and polymethacrylate which are mixed in any proportion;
the disintegrating agent is selected from one or more than two of starch, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, croscarmellose sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl methylcellulose, microcrystalline cellulose and methylcellulose, and is mixed at any ratio;
the glidant is selected from one or a mixture of more than two of colloidal silicon dioxide, powdered cellulose, magnesium trisilicate, silicon dioxide and talcum powder which are mixed in any proportion;
the lubricant is selected from one or more than two of calcium stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, microcrystalline cellulose, sodium benzoate, sodium chloride, sodium lauryl sulfate, sodium stearyl fumarate, talcum powder, zinc stearate and polyethylene glycol which are mixed in any proportion;
the flavoring agent is selected from one or more than two of essence and sweetener, and is a mixture obtained by mixing the essence and the sweetener in any proportion.
11. The formulation according to any one of claims 8 to 10, wherein the formulation is an oral formulation.
12. The formulation of claim 11, wherein the oral formulation is a powder, granule, pellet, capsule, tablet, solution, or lozenge.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019108517593 | 2019-09-10 | ||
| CN201910851759 | 2019-09-10 | ||
| PCT/CN2020/113105 WO2021047437A1 (en) | 2019-09-10 | 2020-09-02 | Pharmaceutical composition for treating viral influenza and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114502150A CN114502150A (en) | 2022-05-13 |
| CN114502150B true CN114502150B (en) | 2023-03-24 |
Family
ID=74866856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080062567.5A Active CN114502150B (en) | 2019-09-10 | 2020-09-02 | Pharmaceutical composition for treating viral influenza and preparation thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114502150B (en) |
| WO (1) | WO2021047437A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022089261A1 (en) * | 2020-10-29 | 2022-05-05 | 广东众生睿创生物科技有限公司 | Crystal form of pyrimidine derivative and preparation method therefor |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103492381A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| CN104151312A (en) * | 2009-06-17 | 2014-11-19 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| CN107759571A (en) * | 2016-08-16 | 2018-03-06 | 广东东阳光药业有限公司 | Inhibitors of influenza viruses replication and its application method and purposes |
| WO2018041263A1 (en) * | 2016-09-05 | 2018-03-08 | 广东众生药业股份有限公司 | Anti-influenza virus pyrimidine derivative |
| CN108276401A (en) * | 2017-01-05 | 2018-07-13 | 广东东阳光药业有限公司 | Inhibitors of influenza viruses replication and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11535613B2 (en) * | 2018-03-05 | 2022-12-27 | Guangdong Raynovent Biotech Co., Ltd. | Crystal form and salt form of pyridoimidazole compound and preparation method therefor |
-
2020
- 2020-09-02 WO PCT/CN2020/113105 patent/WO2021047437A1/en active Application Filing
- 2020-09-02 CN CN202080062567.5A patent/CN114502150B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104151312A (en) * | 2009-06-17 | 2014-11-19 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| CN103492381A (en) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | Inhibitors of influenza viruses replication |
| WO2017133670A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza |
| CN107759571A (en) * | 2016-08-16 | 2018-03-06 | 广东东阳光药业有限公司 | Inhibitors of influenza viruses replication and its application method and purposes |
| WO2018041263A1 (en) * | 2016-09-05 | 2018-03-08 | 广东众生药业股份有限公司 | Anti-influenza virus pyrimidine derivative |
| CN108276401A (en) * | 2017-01-05 | 2018-07-13 | 广东东阳光药业有限公司 | Inhibitors of influenza viruses replication and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice;SMEE Donald F.等;《Antiviral Research》;20161019;第136卷;第45-50页 * |
| Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial;FINBERG Robert W.等;《The Journal of Infectious Diseases》;20181114;第219卷;第1026-1034页 * |
| Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit;BYRN Randal A.等;《Antimicrobial Agents and Chemotherapy》;20150331;第59卷(第3期);第1569-1582页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114502150A (en) | 2022-05-13 |
| WO2021047437A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210008072A1 (en) | Formulations of azaindole compounds | |
| AU2012276114B2 (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
| WO2019029319A1 (en) | Composite product containing limonin compound and biguanide compound | |
| KR20220016105A (en) | Compounds for treating gout or hyperuricemia | |
| CN114502150B (en) | Pharmaceutical composition for treating viral influenza and preparation thereof | |
| KR101902567B1 (en) | Fluorosubstituted (3R,4R,5S)-5-guanidino-4-acetamido-3-(pentan-3-yloxy)cyclohexene-1- carboxylic acids, their esters and use thereof | |
| JP7398547B2 (en) | Combination products containing limonoid compounds and alpha-glucosidase inhibitors | |
| JP7383125B2 (en) | Combination products containing limonoid compounds and thiazolidinedione compounds | |
| JP7383124B2 (en) | Combination products containing limonoid compounds and DPP-4 inhibitors | |
| CN113116899B (en) | Pharmaceutical composition for treating influenza and preparation containing pharmaceutical composition | |
| CN108658843B (en) | Acetylbenzylamine piperidine amide derivative and application thereof as cerebral nerve protective agent | |
| MX2008010394A (en) | Intravenous antiviral treatments. | |
| CN113121337B (en) | Phenoxyaromatic acid with cyclopropyl and pharmaceutically acceptable salt thereof, and preparation method and application thereof | |
| CN107286115B (en) | N- (5-arylmethylthiazol-2-yl) piperazinylamides and their use as NA inhibitors | |
| CN107344920A (en) | A kind of Peramivir sesquialter hydrate compound | |
| CN108794358B (en) | Substituted benzenesulfonyl compounds and application thereof in preparing medicines | |
| CN118290385A (en) | Genistein and picolinic acid eutectic crystal, preparation method, pharmaceutical composition and application thereof | |
| CN117903056A (en) | 2-Substituted acetamido benzamide derivative and application thereof in preparation of anti-influenza virus drugs | |
| CN101613343B (en) | Caderofloxacin lactate crystals I and II and preparation method thereof | |
| JP2022536955A (en) | Diclofenamide composition and method of use | |
| NZ618801B2 (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
| CZ200085A3 (en) | Medicament against heart disorders and pharmaceutical preparation containing SSRI |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |